EyePoint (EYPT) Free Cash Flow (2010 - 2026)
EyePoint (EYPT) posted Free Cash Flow of -$80.6 million for Q1 2026, down 18.18% sequentially from -$68.2 million in Q4 2025, and down 51.7% YoY from -$167.0 million in Q1 2025.
EyePoint (EYPT) Free Cash Flow (2010 - 2026) Analysis & Trends
EyePoint has reported Free Cash Flow for 17 years, with the latest figure at -$80.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 51.7% year-over-year to -$80.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$270.9 million (down 78.52% YoY) and the FY2025 annual result came in at -$243.4 million, down 86.82% from the prior year.
- Free Cash Flow fell to -$80.6 million in Q1 2026 per EYPT's latest filing, from -$68.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $57.5 million in Q2 2023 and troughed at -$80.6 million in Q1 2026.
- A 5-year average of -$30.6 million and a median of -$23.1 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 397.33% in 2023, then plunged 215.19% in 2025.
- Over 5 years, Free Cash Flow stood at -$13.2 million in 2022, then sank by 75.43% to -$23.1 million in 2023, then tumbled by 62.18% to -$37.5 million in 2024, then plunged by 82.08% to -$68.2 million in 2025, then slipped by 18.18% to -$80.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$80.6 million, -$68.2 million, and -$59.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -62.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.41 Mn |
| Jun 30, 2026 | -62.41 Mn |
| Mar 31, 2026 | -80.65 Mn |
| Mar 31, 2026 | -80.65 Mn |
| Dec 31, 2025 | -68.24 Mn |
| Dec 31, 2025 | -68.24 Mn |
| Sep 30, 2025 | -59.38 Mn |
| Sep 30, 2025 | -59.38 Mn |
| Jun 30, 2025 | -62.61 Mn |
| Jun 30, 2025 | -62.61 Mn |
| Mar 31, 2025 | -53.16 Mn |
| Mar 31, 2025 | -53.16 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Sep 30, 2024 | -41.23 Mn |
| Sep 30, 2024 | -41.23 Mn |
| Jun 30, 2024 | -19.86 Mn |
| Jun 30, 2024 | -19.86 Mn |
| Mar 31, 2024 | -31.71 Mn |
| Mar 31, 2024 | -31.71 Mn |